von Itzstein MS, Burns TF, Dowell JE, Horn L, et al. Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer. Clin Cancer Res 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722.
PMID: 39651955